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Abstract 
To expand the structure-activity relationships of fosmidomycin and FR900098, two potent 
antimalarials interfering with the MEP-pathway, we decided to replace a methylene group in 
β-position of the phosphonate moiety of these leads by an oxygen atom. β-oxa-FR900098 (11) 
proved equally active as the parent compound.  
When applied to 4-[hydroxyl(methyl)amino]-4-oxobutyl phosphonic acid, featuring a 
hydroxamate instead of the retrohydroxamate moiety, a β-oxa modification yielded a 
derivative (13) with  superior activity against a 3D7 P. falciparum strain than fosmidomycin, 
while a γ-oxa modification resulted in less active derivatives.  
A bis(pivaloyloxymethyl)ester of phosphonate 13 proved twice as active in inhibiting cultured 
parasites than a similar prodrug of FR900098.  
 
Keywords: Isoprenoid biosynthesis; Fosmidomycin; DOXP Reductoisomerase; 
Methylerythritol phosphate pathway 
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1. Introduction 
1-Deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) catalyzes the conversion of 1-
deoxy-D-xylulose 5-phosphate (DOXP, 1) to 2-C-methyl-D-erythritol 4-phosphate (MEP, 3). 
This conversion involves two consecutive steps (Figure 1). The enzyme first catalyzes an 
intramolecular rearrangement of DOXP into the intermediate 2-C-methyl-D-erythrose 4-
phosphate (2). This step requires a divalent metal ion to induce partial positive charge on the 
C-2 carbon, allowing the C-4 atom to attack it. Several studies have been reported on the 
mechanism of this isomerisation step.1
DXR is one of the enzymes involved in the MEP pathway for the biosynthesis of isoprenoids. 
As it is present in most eubacteria, green algae, and the plastids of higher plants, but not in 
humans,
 A second step involves an NADPH-dependent 
reduction of the aldehyde intermediate. 
2 this pathway has attracted considerable interest for the development of new and safe 
antibiotics as well as herbicides. Furthermore, the MEP pathway has been found in 
Plasmodium spp. that harbour this pathway in their apicoplast compartments.3 The discovery 
that fosmidomycin (4), a metabolite isolated from Streptomyces lavendulae in the late 1970s,4
3
 
efficiently inhibits P. falciparum growth by targeting DXR,  catalyzed research on the 
synthesis of analogues of this phosphonate and its acetyl congener FR900098 (5). Most 
reported efforts toward the synthesis of fosmidomycin analogues involve modifications of the 
retrohydroxamate5 and phosphonate moieties.6
Only recently, some studies were reported on analogues modified at the three carbon spacer 
that connects the retrohydroxamate and phosphonate functionalities.
 Modifications of the phosphonate group are 
generally directed towards improving the relatively poor oral availability of fosmidomycin. 
By masking the phosphonic acid moiety of FR900098 as acyloxyalkyl esters, we were able to 
improve the activity in mice infected with P. vinckei.  
7 The X-ray structural 
data that are available today should aid in the defining of the structural requirements for the 
 4 
design of potent DXR inhibitors. In a recent ternary complex of DXR with fosmidomycin and 
NADPH with a tight-binding conformation, hydrophobic contacts were observed between the 
three carbon spacer and the rigid part of the binding site or with the partially ordered catalytic 
loop.8
Recently, Proteau and coworkers described the synthesis of the phosphate analogues of 
fosmidomycin (6) and FR900098 (7).
  
9 The former had previously been isolated from 
Pseudomonas fluorescens PK-52 and is known as fosfoxacin.10
Compounds 10 and 11 are analogues of fosmidomycin and FR900098, respectively, in which 
the β-methylene function was replaced by an oxygen atom. Since a phosphonomethoxy group 
has been successfully employed as a stable iso-electronic alternative of a methyl phosphate 
moiety to produce antiviral nucleosides,
 The latter proved to be a very 
potent inhibitor of Synechocystis DXR. These results prompted us to report our investigations 
on related series of β- and γ-oxa analogues 10-15. 
11
On the one hand, the bridging oxygen of the phosphate group of DOXP may be involved in 
interactions with amino acids in the binding site.
 compounds 10 and 11 were selected as possible 
bioisosteres of 6 and 7. 
12
12
 Since only hydrophobic contacts with the 
methylene linker were reported, the replacement of the β- or γ-methylene groups by an 
oxygen atom in search for hydrogen bonding seems less compelling. On the other hand, the 
introduction of the electronegative oxygen atom could cause a perturbation of the electronic 
properties, in casu the deprotonation of the phosphonate group  or hydroxamate group, 
which becomes slightly more acidic. As a consequence of the logical decrease of the second 
pKa, the phosphonate could appear rather in its doubly ionised form, which is more 
favourable for an ideal binding. However, it can be concluded that differences in ionisation 
may contribute to a better binding, if the introduction of an oxygen in β-position gives better 
activity instead of a methylene moiety. Analogues 12 and 13 combine the β-oxa modification 
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with a hydroxamic acid moiety, as generally found as metal-binding group in matrix 
metalloproteinase inhibitors. Rohmer and coworkers reported that such metal chelating group, 
when replacing the N-hydroxyformamido moiety of fosmidomycin, as in compound 8 or its 
N-methyl analogue 9, yielded potent inhibitors of DXR which were also capable to inhibit E. 
coli growth.5b Poulter and Walker reported an analogue of DOXP in which the acetyl was 
replaced by a hydroxamic acid, but it did not inhibit the enzyme,13
8
 probably because the 
molecule no longer fit in the confined volume of the active site, as a consequence of its one-
atom longer chain. This is consistent with the recently reported X-ray structure.  
Analogues 14 and 15, which are constitutional isomers of 12 and 13, were also synthesized. 
They combine a hydroxamic acid moiety with an oxygen in γ-position that could possibly 
mimic the C4 hydroxyl group present in the substrate, known to be involved in hydrogen 
bonding with Glu152, Asn227 and Lys228.8 
Prompted by the instability of phosphonic acid 13, we set out on the synthesis of its 
bis(pivaloyloxymethyl)ester analogue 17. 
 
2. Results and discussion 
 
Scheme 1 depicts the synthesis of analogues 10 and 11. Retrohydroxamic acids 21 and 22, 
obtained by acylation of O-benzylhydroxylamine 20, were treated with paraformaldehyde and 
potassium tert-butoxide to give the hydroxymethylated products 23 and 24, which were 
subsequently converted to the chlorides 25 and 26 as reported by Zhu et al.14 Since attempts 
to crystallize the chlorides led to hydrolysis to alcohols 23 and 24, crude 25 and 26 were 
directly used in the Williamson synthesis with 19. Addition of one equivalent of NaH did not 
prove effective to increase the moderate yield. Compound 19 was prepared by a neat reaction 
with dibenzyl phosphite, paraformaldehyde and triethylamine. The perbenzylated compounds 
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27 and 28 were finally deprotected by catalytic hydrogenation to yield the phosphonic acids 
10 and 11, which were purified by reversed phase HPLC. Since the N,O-acetal in 27 and 28 is 
acid sensitive, it was very important to use neutral Pd/C catalyst to prevent cleavage. Sajiki et 
al. reported a remarkable supplier dependent disparity in properties of Pd/C catalysts. Pd/C 
catalysts of some suppliers appeared to be acidic enough to cleave triethylsilylethers without 
H2.15
The synthesis of the hydroxamate 12 and its N-methyl analogue 13 is shown in Scheme 2. 
Diethylhydroxymethyl phosphonate (29) was reacted with ethylbromoacetate in the presence 
of two equivalents NaH in THF to give 30 in 80% yield. Hydrolysis of 30 with one equivalent 
of sodium hydroxide followed by neutralisation gave acid 31 in 94% yield. An attempt to 
react diethylhydroxymethyl phosphonate directly with chloroacetic acid in the presence of 
two equivalents of NaH resulted in a poor yield. Treatment of carboxylic acid 31 with 
carbonyldiimidazole and O-benzylhydroxylamine afforded the N-benzyloxyamide 32. A 
possible simplification consists of the direct conversion of the ester 30 to the N-
benzyloxyamide 32 by a recently published procedure.
 β-Oxa analogue 11 proved to be stable in H2O for more than two weeks, as revealed by 
1H-NMR. 
16
The synthesis of the N-hydroxy carbamates 14 and 15 is depicted in Scheme 3. Treatment of 
dimethylhydroxyethyl phosphonate (34) with carbonyldiimidazole and benzylhydroxyl amine 
afforded 37. N-methylation, as described for 34, yielded 39. The benzyl protecting groups of 
37 and 39 were removed by catalytic hydrogenolysis (Pd/C) to give 38 and 40. Finally, the 
phosphonate esters were deprotected as outlined above. 
 A methyl group was introduced by 
deprotonation of 32 with NaH in THF followed by addition of methyl iodide to give 34. 
Finally, hydroxamic acid 12 and its N-methylated analogue 13 were obtained after catalytic 
debenzylation (Pd/C) and deprotection of the phosphonate moieties with two equivalents of 
bromotrimethylsilane in dichloromethane.  
 7 
The synthesis of the bis(pivaloyloxymethyl)ester of 13 from its diethyl ester 35 was realized 
under standard conditions.  
 
All target compounds were tested for inhibition of recombinant E. coli DXR (Table 1). The 
assay was based on the photometric measurement of the NADPH turnover associated with the 
DXR catalysed reaction.17
In the series with the inversed hydroxamates and carbamates the N-methyl substituted 
analogues proved superior to their non-methylated analogues. Compound 9, made by Rohmer 
et al., was marginally less active than fosmidomycin and FR900098 in the E. coli DXR 
inhibition assay. The results of 13 and 15 showed that introduction of an oxygen atom in the 
propyl chain is more favourable in the β-position of the phosphonate moiety than in γ-position 
of the phosphonate moiety. Introduction of an oxygen atom in the γ-position of the 
phosphonate moiety generates carbamates 14 and 15 which were weak in inhibiting E. coli 
DXR, as shown by the relatively high IC50 values. In contrast, compound 13 proved to be 
almost equipotent to FR900098 and at least as active as compund 9. Comparison of analogues 
11 and 13 demonstrated that, when combined with a β-oxa modification, the hydroxamate 
seems favourable to the N-hydroxyacetamido group as metal chelating moiety. Inhibitor 13, 
when assayed as a fresh solution, is slightly more potent than 11. The introduction of an 
oxygen atom in the linker does not contribute favourably to the hydrophobic interactions 
around the linker which are present according to the crystal structure of DXR from Sweeney 
et al., although on this E. coli DXR inhibition assay analogue 13 was comparably potent to 
analogue 9 with the methylene linker. This points out that an oxygen atom in β-position 
slightly influences the ionisation and as such the binding, even if hydrophobic interactions are 
playing a part. Likewise, it is also possible that the ether linkage is still hydrophobic enough 
 Fosmidomycin and FR900098 were included as reference 
compounds. 
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to ensure a tight bonding of the inhibitor. In order to confirm that there is no hydrogen 
bonding involved, docking experiments would be useful. 
Because of the varying IC50 values obtained with 13, we assessed its stability and inferred that 
in aqueous solution, slow but significant degradation of this compound took place. Hence, we 
evaluated its bis(pivaoyloxymethyl)ester 17, which was compared to the same ester prodrug 
of FR900098.  While both compounds were unable to inhibit E. coli DXR, 17 proved 
approximately twice more potent in inhibiting the growth of a 3D7 P. falciparum strain, 
further warranting in vivo evaluation of this compound.  
Furthermore, compound 11 outperformed its formyl analogue 10. An opposite trend was 
observed in the fosmidomycin/FR900098 couple, where fosmidomycin is superior to 
FR900098. Nevertheless, in this series of compounds fosmidomycin stays the best inhibitor 
on this E. coli DXR inhibition assay.  
In summary, we established an efficient and reliable synthesis for β- and γ-oxa fosmidomycin 
analogues. Analogue 13, which combines a β-oxa modification with a hydroxamate moiety 
was almost as potent in inhibiting E. coli DXR as FR900098.  
 
3. Experimental 
3.1. Chemicals and solvents 
Most chemicals were obtained from Sigma-Aldrich or Acros Organics and were used without 
further purification. Compound 16 was obtained as decribed earlier.5b All reactions were 
carried out under inert (N2) atmosphere. 
 
3.2. Chromatography 
Precoated Merck silica gel F254 plates and precoated Macherey-Nagel (Düren, Germany) 
silica gel F254 plates were used for TLC and spots were examined under UV light at 254 nm 
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and revealed by a phosphomolybdic-cerium sulfate solution, iodine vapour or bromocresol 
green solution. Column chromatography was performed on ICN silica gel (63-200 μM).  
 
3.3. Instruments and analyses 
NMR spectra were obtained with a Varian Mercury 300 spectrometer. Chemical shifts are 
given in parts per million (ppm) (δ relative to residual solvent peak, in the case of CDCl3 7.26 
ppm for 1H and 77.4 ppm for 13C. Coupling constants are expressed in Hz. Abbreviations used 
are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br. s = broad signal. All 
signals assigned to hydroxyl and to amino groups were exchangeable with D2O. Structural 
assignment was confirmed with COSY, DEPT and/or HMQC if necessary. Mass spectra and 
exact mass measurements were performed on a quadrupole/orthogonal-acceleration time-of-
flight (Q/oaTOF) tandem mass spectrometer (qTof 2, Micromass, Manchester, U.K.) 
equipped with a standard electrospray ionization (ESI) interface. Samples were infused in an 
acetonitrile/water (1:1) mixture at 3μL/min.  
 
3.4. Dibenzyl hydroxymethylphosphonate (19)  
Dibenzyl phosphite (20 mL, 76.27 mmol), triethylamine (10.60 mL, 76.27 mmol), and 
paraformaldehyde (2.45 g, 130 mmol) were mixed in a reaction vessel. The vessel was tightly 
sealed and the mixture was mechanically stirred for 12 h at 90 °C. All volatile components 
were subsequently removed under reduced pressure, and the remaining semisolid was 
dissolved in 25 mL of CH2Cl2. The solution was successively washed with saturated aqueous 
solutions of NH4Cl, K2CO3 and again NH4Cl, dried with MgSO4 and the solvent removed 
under reduced pressure. The residue, a pale-yellow oil, was purified by column 
chromatography (CH2Cl2/ethyl acetate, 2:1 to CH2Cl2/acetone 1:1, after all benzyl alcohol had 
eluted from the column) to yield compound 19 (12.48 g, 42.7 mmol, 56%).  
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1H-NMR (300 MHz, CDCl3): δ = 3.92 (d, J = 5.6 Hz, 2 H, CH2P), 5.06 (m, 4 H, CH2Ph), 7.34 
(s, 10 H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 57.66 (d, J = 160.7 Hz, CH2P), 68.27 (d, J = 6.6 Hz 
OCH2Ar), 128.26 (=CH), 128.78 (=CH), 128.86 (=CH), 136.29 (=C) ppm.  
Exact mass (ESI-MS): calculated for C15H16O4P [M-H]-: 291.0785; found: 291.0772. 
 
3.5. N-(benzyloxy)formamide (21) 
Formic acid (1.18 mL, 31.3 mmol) was dissolved in dry CH2Cl2 (60 mL). To this solution 
carbonyldiimidazole (5.08 g, 31.3 mmol) was added. After stirring for 30 min a suspension of 
benzylhydroxylamine hydrochloride (5 g, 31.3 mmol) in 31 mL of CH2Cl2 containing Et3N 
(4.35 ml, 31.3 mmol) was added. When TLC revealed disappearance of all the starting 
material, the reaction mixture was diluted with 150 mL CH2Cl2 and washed six times with 1N 
HCl (100 mL). The organic layer was dried over MgSO4, concentrated under reduced pressure 
and the residue purified by chromatography (CH2Cl2/MeOH 95:5) to yield 4.13 g of N-
(benzyloxy)formamide 21 (yield 87%) as a pale yellow oil. 
1H-NMR (300 MHz, CDCl3): mixture of amide rotamers δ = 4.74 and 4.80 (2 × s, 2 H, 
CH2Ph, minor and major), 7.30 (m, 5 H, arom. H), 7.67 and 8.01 (2 × s, 1 H, C(O)H, major 
and minor), 9.60 and 10.32 (2 × s, 1 H, NH, minor and major) ppm. 
13C-NMR (75 MHz, CDCl3): mixture of amide rotamers δ = 78.56 and 81.05 (2 × s, OCH2Ar, 
major and minor), 128.79 (=CH), 129.07 (=CH), 129.41 (=CH), 135.09 (=C), 158.35 and 
165.08 (2 × s, C(O)H, major and minor) ppm.  
Exact mass (ESI-MS): calculated for C8H10NO2 [M+H]+: 152.0712; found: 152.0426. 
 
3.6. N-(benzyloxy)acetamide (22) 
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O-benzylhydroxylamine hydrochloride (1g, 6.2 mmol) was dissolved in CH2Cl2 (20 mL) and 
triethylamine (1 mL, 6.8 mmol) and stirred for 1 h. This suspension was treated with acetyl 
chloride (0.5 mL, 6.8 mmol) dropwise and stirred for 1.5 h at room temperature. The reaction 
mixture was diluted with 60 mL of CH2Cl2 and washed with 100 mL of water. The organic 
solvent was removed under reduced pressure and the residue was purified (CH2Cl2/MeOH 
95:5) to yield 0.43 g of N-(benzyloxy)acetamide 22 (yield 86%) as white crystals.  
1H-NMR (300 MHz, CDCl3): mixture of amide rotamers δ = 1.80 and 1.96 (2 × s, 3 H, 
C(O)CH3, major and minor), 4.77 and 4.84 (2 × s, 2 H, CH2Ph, minor and major), 7.30 (m, 5 
H, arom. H), 8.57 and 9.59 (2 × s, 1 H, NH, minor and major) ppm. 
13C-NMR (75 MHz, CDCl3): mixture of amide rotamers δ = 19.95 and 19.96 (2 × s, CH3, 
minor and major); 78.24 and 79.53 (2 × s, OCH2Ar, major and minor), 128.74 (=CH), 128.82 
(=CH), 129.32 (=CH), 135.67 (=C), 168.45 and 175.23 (2 × s, C(O)CH3, major and minor) 
ppm.  
Exact mass (ESI-MS): calculated for C9H12NO2 [M+H]+: 166.0868; found: 166.0875. 
 
3.7. General method for hydroxymethylation of 21 and 22. 
A mixture of the N-benzyloxyamide (5.71 mmol), paraformaldehyde (0.26 g, 8.56 mmol) and 
tBuOK (0.064 g, 0.57 mmol) was heated, in the absence of solvent, at 60 °C during 4 h. The 
reaction mixture was cooled and diluted with water (80 mL). After extraction with CH2Cl2 (3 
x 80 mL) the organic layer was dried over anhydrous Na2SO4 and evaporated in vacuo. The 
residue was purified by chromatography (hexane/ethyl acetate, 1:1 for 24 or 
pentane/acetone/Et3N, 6:4:0.1 for 23 ) to give 23 and 24 in 79 and 48% yield as white solids. 
 
3.7.1. N-(benzyloxy)-N-(hydroxymethyl)formamide (23) 
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1H-NMR (300 MHz, CDCl3): δ = 3.91 (br. s, 1 H, OH), 4.76 (s, 2 H, CH2Ph), 4.98 (br. s, 2 H, 
HOCH2), 7.37 (m, 5 H, arom. H), 8.08 (s, 1H, O=CH) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 69.55 (s, HOCH2, major), 73.10 (s, HOCH2, minor), 77.71 
(s, CH2Ph, minor), 79.81 (s, CH2Ph, major), 128.96 (=CH), 129.37 (=CH), 129.87 (=CH), 
134.54 (=C), 159.48 (s, O=CH, minor), 164.27 (s, C(O)H, major) ppm.  
Exact mass (ESI-MS): calculated for C9H12NO3 [M+H]+: 182.0817; found: 182.0832.  
 
3.7.2. N-(benzyloxy)-N-(hydroxymethyl)acetamide (24) 
1H-NMR (300 MHz, CDCl3): δ = 2.06 (s, 3 H, C(O)CH3), 3.96 (br. s, 1 H, OH), 4.93 (s, 2 H, 
CH2Ph), 5.03 (br. s, 2 H, HOCH2), 7.38 (m, 5 H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 20.86 (s, CH3), 71.17 (s, HOCH2), 78.45 (s, OCH2Ar), 
128.94 (=CH), 128.94 (=CH), 128.94 (=CH), 134.65 (=C), 174.26 (s, C(O)CH3) ppm.  
Exact mass (ESI-MS): calculated for C10H14NO3 [M+H]+: 196.0974; found:196.0981.  
 
3.8. General method for synthesis of  N-(benzyloxy)-N-(chloromethyl)formamide (25) 
and N-(benzyloxy)-N-(chloromethyl)acetamide (26) 
To a cooled solution (10 °C) of 23 or 24 (2.7 mmol) in 5.5 mL of CH2Cl2 was added thionyl 
chloride (0.55 mL, 7.5 mmol). After stirring for 30 min, the mixture was evaporated under 
vacuum to yield an oily residue that could be solidified by adding a drop of hexane and 
connecting the flask to high vacuum. In our hands it was not possible to recrystallize 26 from 
ethyl acetate due to hydrolysis to the alcohol 24. Therefore, 26 was directly used in the next 
step without further purification. The same holds for 25. 
 
3.9. Dibenzyl(N-(N-benzyloxyformamido)methoxy)methylphosphonic acid (27) 
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To a solution of crude 25 (~ 0.37 mmol) in 5 mL of CH2Cl2 was added a solution 19  (0.16 g, 
0.54 mmol) in 5 mL of CH2Cl2. After stirring for 16 h at room temperature the mixture was 
evaporated to dryness and purified by column chromatography (CH2Cl2/ethyl acetate, 2:1), 
affording 27 (35 mg, 21%) as a clear oil. 
1H-NMR (300 MHz, CDCl3): δ = 3.75 – 3.87 (m, 2H, CH2P), 4.74 – 5.15 (m, 8H, NCH2O and 
PhCH2O), 7.28 – 7.35 (m, 15H, arom. H), 8.07 and 8.15 (br. s and br. s, 1H, C(O)H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 63.60 (d, 1JC,P = 171.0 Hz, CH2P), 68.24 and 68.32 (2 × s, 
PhCH2), 80.04 (NCH2O), 128.33 (=CH), 128.86 (=CH), 129.37 (=CH), 129.80 (=CH), 134.44 
(=C), 136.18 (=C), 164.25 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C24H27NO6P [M+H]+: 456.1576; found: 456.1580. 
 
3.10. Dibenzyl(N-(N-benzyloxyacetamido)methoxy)methylphosphonic acid (28) 
To a solution of crude 26 (~ 2.5 mmol) in 2 mL of CH2Cl2 was added a solution 19 (1.46 g, 5 
mmol) in 3 mL of CH2Cl2. After stirring for 16 h at room temperature the mixture was 
evaporated to dryness and purified by column chromatography (CH2Cl2/ethyl acetate, 2:1) to 
give 28 (0.44 g, 38%) as a clear oil. 
1H-NMR (300 MHz, DMSO-d6): δ = 2.06 (s, 3H, C(O)CH3), 3.97 (d, J = 8.8 Hz, 2H, CH2P), 
4.92 (s, 2H, NCH2O), 5.02 (s, 2H, PhCH2), 5.05 (d, J = 1.5 Hz, 2H, PhCH2), 5.08 (d, J = 2.0 
Hz, 2H, PhCH2), 7.30 – 7.40 (m, 15H, arom. H) ppm. 
13C-NMR (75 MHz, DMSO-d6): δ = 21.16 (CH3), 62.76 (d, 1JC,P = 219.3 Hz, CH2P), 67.70 
and 67.78 (2 × s, PhCH2), 77.41 (NCH2O), 128.48 (=CH), 128.93 (=CH), 129.13 (=CH), 
129.15 (=CH), 129.40 (=CH), 130.10 (=CH),  135.35 (=C), 137.03 (d, JC,P = 6.1 Hz, =C), 
173.18 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C25H29NO6P [M+H]+: 470.1733; found: 470.1728. 
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3.11. General procedure for the benzyl deprotection of 27 and 28 
A solution of compound 27 or 28 (140 mg) in MeOH (3 mL) was hydrogenated at 
atmospheric pressure in the presence of Pd 10 wt. % on activated carbon (70 mg). After 3 h 
stirring the reaction mixture was filtered over a celite pad. The solvent was removed under 
vacuum and the crude mixture was purified by column chromatography on silica gel 
(CH2Cl2/MeOH 90:10). Phosphonic acids 10 and 11 were purified according to the 
purification of compounds 12-15 (see further). 
 
3.11.1. (N-(N-hydroxyformamido)methoxy)methylphosphonic acid (10): Yield: 34 % 
according to HPLC analysis. 
1H-NMR (300 MHz, D2O): δ = 3.68 (d, JH,P = 9.4 Hz, 2H, CH2P), 5.01 (s, 2H, OCH2), 7.94 (s, 
1H, C(O)H, minor), 8.21 (s, 1H, C(O)H, major) ppm. 
13C-NMR (75 MHz, D2O): δ = 58.11(d, 1JC,P = 153.88 Hz, CH2P, major), 63.98 (d, 1JC,P = 
153.88 Hz, CH2P, minor), 81.26 (s, OCH2, major), 81.40 (s, OCH2, minor), 160.19 (s, C=O, 
minor), 161.032 (s, C=O, major) ppm. 
31P-NMR (121 MHz, D2O): δ = 15.05 ppm. 
Exact mass (ESI-MS): calculated for C3H7NO6P [M-H]-: 184.0010; found: 184.0025. 
 
3.11.2. (N-(N-hydroxyacetamido)methoxy)methylphosphonic acid (11): Yield:  43 % 
according to HPLC analysis. 
1H-NMR (300 MHz, D2O): δ = 2.07 (s, 3H, CH3, major), 2.08 (s, 3H, CH3, minor), 3.43 (d, 
JH,P = 8.9 Hz, 2H, CH2P, major), 3.49 (d, JH,P = 8.9 Hz, 2H, CH2P, minor), 4.87 (s, 2H, OCH2, 
major), 4.95 (s, 2H, OCH2, minor) ppm. 
 15 
13C-NMR (75 MHz, D2O): δ = 19.79 (CH3), 66.38 (d, 1JC,P = 137.0 Hz, CH2P, major), 70.87 
(d, 1JC,P = 137.0 Hz, CH2P, minor), 77.78 (s, OCH2, major), 77.93 (s, OCH2, minor), 175.74 
(C=O) ppm. 
31P-NMR (121 MHz, D2O): δ = 15.16 ppm. 
Exact mass (ESI-MS): calculated for C4H11NO6P [M+H]+: 200.0324; found: 200.0632. 
 
3.12. Diethyl ((ethoxycarbonyl)methoxy)methylphosphonate (30) 
Sodium hydride (400 mg, 11.9 mmol) was added to a solution of diethylhydroxymethyl 
phosphonate (1 g, 5.9 mmol) in THF (26 mL) and stirred for 1 h. Subsequently, ethyl 
bromoacetate (1.29 g, 7.7 mmol) was added and, after 3 h, the reaction was quenched with 
sat. NH4Cl (aq.). EtOAc was added, the two phases separated and the aqueous layer further 
extracted with three portions of EtOAc (100 mL). The combined organic layers were dried 
over MgSO4 and the solvent was removed under reduced pressure. The residue was purified 
by flash chromatography (CH2Cl2/MeOH, 95:5) to give 30(1.21 g, 80%) as an oil. 
1H-NMR (300 MHz, CDCl3): δ = 1.25 (t, J = 7.0 Hz, 6H, C(O)OCH2CH3), 1.32 (t, J = 7.0 Hz, 
6H, POCH2CH3), 3.91 (d, JH,P = 8.5 Hz, 2H, CH2P), 4.12 – 4.22 (m, 8H, C(O)CH2O and 
POCH2CH3) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 14.37 (C(O)OCH2CH3), 16.64 (d, 3JC,P = 5.8 Hz, 
POCH2CH3), 61.19 (C(O)OCH2CH3), 62.79 (d, 2JC,P = 6.3 Hz, POCH2CH3), 65.30 (d, 1JC,P = 
165.5 Hz, CH2P), 69.66 (d, 3JC,P = 11.2 Hz, C(O)CH2O), 169.79 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C9H20O6P [M+H]+: 255.0998; found: 255.0987. 
 
3.13. 2-((Ethoxyphosphono)methoxy)acetic acid (31) 
A solution of 28 (1.21 g, 4.8 mmol) in 4.8 mL 1N aq. NaOH was stirred for 2 h at 30 °C. 
When the hydrolysis was finished, as indicated by TLC, the reaction mixture was neutralized 
 16 
with 1N HCl until pH ≈ 6. The desired carboxylic acid was extracted with CH2Cl2 (5 × 50 
mL) and EtOAc (3 × 50 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography (CH2Cl2/MeOH/ HCOOH, 
95:5:0.1) afforded 31 (1.0 g, 94%). The carboxylic acid was visualized on TLC with 
bromocresol green. 
1H-NMR (300 MHz, CDCl3): δ = 1.36 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.98 (d, JH,P = 8.2 Hz, 
2H, CH2P), 4.16 – 4.26 (m, 6H, C(O)CH2O and OCH2CH3), 6.79 (br. s, 1H, OH) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 16.61 (d, 3JC,P = 5.8 Hz, OCH2CH3), 63.34 (d, 2JC,P = 6.3 Hz, 
OCH2CH3), 65.40 (d, 1JC,P = 165.8 Hz, CH2P), 69.74 (d, 3JC,P = 10.1 Hz, C(O)CH2O), 171.91 
(C=O) ppm. 
Exact mass (ESI-MS): calculated for C7H16O6P [M+H]+: 227.0685; found: 227.0683. 
 
3.14. Diethyl ((benzyloxycarbamoyl)methoxy)methylphosphonate (32) 
Compound 31 (0.80 g, 3.5 mmol) was dissolved in CH2Cl2 (4 mL). To this solution 1.1 eq. 
carbonyldiimidazole (0.60 g, 3.7 mmol) was added. After stirring for 0.5 h, a suspension of 
benzylhydroxylamine hydrochloride (0.59 g, 3.7 mmol) in 4 mL of CH2Cl2 containing Et3N 
(0.38 g, 3.7 mmol) was added. After disappearance of all starting material as indicated by 
TLC, the reaction mixture was diluted with 50 mL CH2Cl2 and washed with 1N HCl (60 mL). 
The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by flash 
chromatography (CH2Cl2/MeOH, 95:5) afforded 32 as an oil in 83% yield (970 mg). 
1H-NMR (300 MHz, CDCl3): δ = 1.31 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.76 (d, JH,P = 8.8 Hz, 
2H, CH2P), 4.07 – 4.17 (m, 6H, C(O)CH2O and OCH2CH3), 4.96 (s, 2H, PhCH2O), 7.34 – 
7.44 (m, 5H, arom. H), 9.46 (br. s, 1H, NH) ppm. 
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13C-NMR (75 MHz, CDCl3): δ = 16.65 (d, 3JC,P = 5.8 Hz, OCH2CH3), 63.01 (d, 2JC,P = 6.6 Hz, 
OCH2CH3), 66.19 (d, 1JC,P = 168.4 Hz, CH2P), 72.33 (d, 3JC,P = 10.1 Hz, CH2), 78.59 
(PhCH2O), 128.78 (=CH), 128.95 (=CH), 129.39 (=CH), 135.0 (=C), 168.91 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C14H23NO6P [M+H]+: 332.1263; found: 332.1272. 
 
3.15. Diethyl ((hydroxycarbamoyl)methoxy)methylphosphonate (33) 
Benzyl deprotection of 32 was essentially performed as described for 10 and 11, yielding the 
title compound in 80% yield (92 mg). 
1H-NMR (300 MHz, CDCl3): δ = 1.30 (m, 6H, OCH2CH3), 3.85 (m, 2H, CH2P), 4.14 (m, 6H, 
C(O)CH2O and OCH2CH3), 10.02 (br. s, 1H, NH) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 16.59 (d, 3JC,P = 5.5 Hz, OCH2CH3), 63.23 (d, 2JC,P = 6.3 Hz, 
OCH2CH3), 65.91 (d, 1JC,P = 166.7 Hz, CH2P), 71.57 (d, 3JC,P = 10.0 Hz, C(O)CH2O), 166.24 
(C=O) ppm. 
Exact mass (ESI-MS): calculated for C8H17NO6P [M+H]+: 254.0794; found: 254.0806. 
 
3.16. Diethyl ((N-(benzyloxy)-N-methylcarbamoyl)methoxy)methylphosphonate (34) 
To solution of 32 (0.51 g, 1.5 mmol) in 16 mL of THF was added sodium hydride (67 mg, 1.7 
mmol) and methyl iodide (0.24 g, 1.7 mmol). The mixture was stirred overnight at room 
temperature, quenched with a saturated solution of NH4Cl (40 mL) and extracted with ether (3 
× 40 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. Purification 
by flash chromatography (CH2Cl2/MeOH, 95:5) afforded 34 (300 mg, 56%). 
1H-NMR (300 MHz, CDCl3): δ = 1.30 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.17 (s, 3H, NCH3), 
3.83 (d, JH,P = 8.2 Hz, 2H, CH2P), 4.09 – 4.19 (m, 4H, OCH2CH3), 4.25 (s, 2H, C(O)CH2O), 
4.77 (s, 2H, PhCH2O), 7.26 – 7.37 (m, 5H, arom. H) ppm. 
 18 
13C-NMR (75 MHz, CDCl3): δ = 16.63 (d, 3JC,P = 5.8 Hz, OCH2CH3), 33.73 (NCH3), 62.71 
(d, 2JC,P = 6.6 Hz, OCH2CH3), 65.11 (d, 1JC,P = 164.7 Hz, CH2P), 69.91 (d, 3JC,P = 11.5 Hz, 
C(O)CH2O), 76.53 (PhCH2O), 129.00 (=CH), 129.42 (=CH), 129.65 (=CH), 134.28 (=C), 
171.13 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C15H25NO6P [M+H]+: 346.1420; found: 346.1408. 
 
3.17. Diethyl ((N-hydroxy-N-methylcarbamoyl)methoxy)methylphosphonate (35) 
Benzyl deprotection of 34 was essentially performed as described for 10 and 11, yielding the 
title compound in 89% yield (140 mg). 
1H-NMR (300 MHz, CDCl3): δ = 1.31 (t, J = 7.0 Hz, 6H, OCH2CH3), 3.19 (s, 3H, NCH3), 
3.91 (d, JH,P = 8.2 Hz, 2H, CH2P), 4.09 – 4.19 (m, 4H, OCH2CH3), 4.41 (s, 2H, C(O)CH2O), 
9.38 (br. s, 1H, OH) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 16.57 (d, 3JC,P = 5.8 Hz, OCH2CH3), 36.03 (NCH3), 63.22 
(d, 2JC,P = 6.6 Hz, OCH2CH3), 65.02 (d, 1JC,P = 166.1 Hz, CH2P), 70.01 (d, 3JC,P = 11.8 Hz, 
C(O)CH2O), 169.83 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C8H19NO6P [M+H]+: 256.0950; found: 256.1052. 
 
3.18. Dimethyl 2-(N-benzyloxycarbonyloxy)ethylphosphonate (37) 
The title compound was prepared in 73% yield from 36 using a similar procedure as described 
for 32. 
1H-NMR (300 MHz, CDCl3): δ = 2.13 (dt, JH,H = 7.3 Hz and JH,P = 18.8 Hz, 2H, CH2P), 3.68 
(d, J = 11.1 Hz, 6H, OCH3), 4.30 (dt, JH,H = 7.6 Hz and JH,P = 12.9 Hz , 2H, CH2CH2P), 4.81 
(s, 2H, PhCH2O), 7.29 – 7.34 (m, 5H, arom. H), 8.15 (br. s, 1H, NH) ppm. 
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13C-NMR (75 MHz, CDCl3): δ = 25.42 (d, 1JC,P = 140.5 Hz, CH2P), 52.73 (d, 2JC,P = 6.6 Hz, 
OCH3), 59.79 (CH2CH2P), 78.78 (PhCH2O), 128.69 (=CH), 128.78 (=CH), 129.32 (=CH), 
135.68 (=C), 157.16 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C12H19NO6P [M+H]+: 304.0950; found: 304.0947. 
 
3.19. Dimethyl 2-(N-hydroxycarbonyloxy)ethylphosphonate (38) 
Benzyl deprotection of 37 was essentially performed as described for 10 and 11, yielding the 
title compound in 98% yield (350 mg). 
1H-NMR (300 MHz, CDCl3): δ = 2.21 (dt, JH,H = 7.0 Hz and JH,P = 18.8 Hz, 2H, CH2P), 3.77 
(d, J = 11.1 Hz, 6H, OCH3), 4.40 (dt, JH,H = 7.0 Hz and JH,P = 15.3 Hz , 2H, CH2CH2P), 7.40 
(br. s, 1H, NH) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 25.45 (d, 1JC,P = 141.4 Hz, CH2P), 52.96 (d, 2JC,P = 6.6 Hz, 
OCH3), 59.82 (CH2CH2P), 158.38 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C5H13NO6P [M+H]+: 214.0481; found: 214.0479. 
 
3.20. Dimethyl 2-(N-benzyloxy-N-methylcarbonyloxy)ethylphosphonate (39) 
The title compound was prepared in 68% yield from 37 using a similar procedure as described 
for 34. 
1H-NMR (300 MHz, CDCl3): δ = 2.03 (dt, JH,H = 7.0 Hz and JH,P = 18.8 Hz, 2H, CH2P), 2.91 
(s, 3H, NCH3), 3.56 (d, J = 10.8 Hz, 6H, OCH3), 4.20 (dt, JH,H = 7.3 Hz and JH,P = 13.2 Hz , 
2H, CH2CH2P), 4.69 (s, 2H, PhCH2O), 7.15 – 7.25 (m, 5H, arom. H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 25.33 (d, 1JC,P = 140.5 Hz, CH2P), 36.89 (NCH3), 52.52 (d, 
2JC,P = 6.3 Hz, OCH3), 60.08 (CH2CH2P), 76.65 (PhCH2O), 128.52 (=CH), 128.70 (=CH), 
129.48 (=CH), 135.47 (=C), 157.06 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C13H21NO6P [M+H]+: 318.1107; found: 318.1111. 
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3.21. Dimethyl-2-(N-hydroxy-N-methylcarbonyloxy)ethylphosphonate (40) 
Benzyl deprotection of 39 was essentially performed as described for 10 and 11, yielding the 
title compound in 97% yield (300 mg). 
1H-NMR (300 MHz, CDCl3): δ = 2.09 (dt, JH,H = 6.2 Hz and JH,P = 18.8 Hz, 2H, CH2P), 3.08 
(s, 3H, NCH3), 3.64 (d, J = 10.8 Hz, 6H, OCH3), 4.40 (dt, JH,H = 6.5 Hz and JH,P = 13.8 Hz , 
2H, CH2CH2P) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 25.27 (d, 1JC,P = 140.5 Hz, CH2P), 38.34 (NCH3), 52.82 (d, 
2JC,P = 6.3 Hz, OCH3), 59.76 (CH2CH2P), 157.22 (C=O) ppm. 
Exact mass (ESI-MS): calculated for C6H15NO6P [M+H]+: 228.0637; found: 228.0624. 
 
3.22. General method for the phosphonate deprotection towards compounds 12, 13, 14 
and 15. 
Esters 33, 35, 38 or 40 (0.39 mmol) were dissolved in CH2Cl2 (1.1 mL) and treated dropwise 
with 2 eq. of TMSBr (0.77 mmol, 83 mg) under N2. The reaction mixture was stirred for 2 h 
at room temperature. After completion of the reaction the volatile compounds were removed 
in vacuo to give the corresponding phosphonic acids. All final compounds were purified using 
a preparative HPLC system on a C18 column (5μm; Phenomenex; Luna; 250 x 21.2 mm) with 
a linear gradient of acetonitrile in 5 mM NH4OAc solution over 20 min at a flow rate of 17.5 
mL/min. The purity of all target compounds was assessed by analytical HPLC (5μm; 
Phenomenex; C18(2); 250 x 4.6 mm) using the same gradient at a flow rate of 1 mL/min. All 
final compounds were obtained as hygroscopic foams or slight yellow oils after lyophilisation. 
For compounds 12 and 13, this procedure was not very efficient since the target compounds 
showed poor retention (elution time: 3.6 min). Nevertheless it permitted to produce a pure 
fraction. 
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3.22.1. ((Hydroxycarbamoyl)methoxy)methylphosphonic acid (12): Yield: 52% according 
to HPLC analysis. 
1H-NMR (300 MHz, D2O): δ = 3.49 (d, JH,P = 9.1 Hz, 2H, CH2P), 3.92 (s, 2H, C(O)CH2O, 
minor), 4.07 (s, 2H, C(O)CH2O, major) ppm. 
13C-NMR (75 MHz, D2O): δ = 69.47 (d, 1JC,P = 152.3 Hz, CH2P), 70.76 (d, 3JC,P = 13.3 Hz, 
C(O)CH2OO), 169.31 (C=O) ppm. 
31P-NMR (121 MHz, D2O): δ = 15.58 ppm. 
Exact mass (ESI-MS): calculated for C3H7NO6P [M-H]-: 184.0010; found: 184.0456. 
 
3.22.2. ((N-hydroxy-N-methylcarbamoyl)methoxy)methylphosphonic acid (13): Yield: 
45% according to HPLC analysis. 
1H-NMR (300 MHz, D2O): δ = 3.16 (s, 3H, NCH3, major), 3.22 (s, 3H, NCH3, minor), 3.51 
(d, JH,P = 8.5 Hz, 2H, CH2P), 4.25 (s, 2H, C(O)CH2O, minor), 4.38 (s, 2H, C(O)CH2O, major) 
ppm. 
13C-NMR (75 MHz, D2O): δ = 36.09 (NCH3), 68.40 (d, 1JC,P = 157.5 Hz, CH2P), 69.37 (d, 
3JC,P = 11.5 Hz, C(O)CH2O), 171.73 (C=O) ppm. 
31P-NMR (121 MHz, D2O): δ = 15.42 ppm. 
Exact mass (ESI-MS): calculated for C4H9NO6P [M-H]-: 198.0166; found: 198.0160. 
 
3.22.3. 2-(N-hydroxycarbonyloxy)ethylphosphonic acid (14): Yield: 71 mg (quantitative). 
1H-NMR (300 MHz, MeOD): δ = 2.14 (dt, JH,H = 7.0 Hz and JH,P = 19.1 Hz, 2H, CH2P), 4.31 
(dt, JH,H = 7.6 Hz and JH,P = 10.6 Hz , 2H, CH2CH2P) ppm. 
13C-NMR (75 MHz, MeOD): δ = 27.51 (d, 1JC,P = 137.0 Hz, CH2P), 59.97 (CH2CH2P), 159.15 
(C=O) ppm. 
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31P-NMR (121 MHz, MeOD): δ = 25.63 ppm. 
Exact mass (ESI-MS): calculated for C3H8NO6P [M-H]-: 184.0010; found: 184.0007. 
 
3.22.4. 2-(N-hydroxy-N-methylcarbonyloxy)ethylphosphonic acid (15): Yield: 153 mg 
(quantitative). 
1H-NMR (300 MHz, MeOD): δ = 2.16 (m, 2H, CH2P), 3.16 (s, 3H, NCH3), 4.32 (m, 2H, 
CH2CH2P) ppm. 
13C-NMR (75 MHz, MeOD): δ = 27.43 (d, 1JC,P = 138.2 Hz, CH2P), 37.68 (NCH3), 60.68 
(CH2CH2P), 157.74 (C=O) ppm. 
31P-NMR (121 MHz, MeOD): δ = 25.92 ppm. 
Exact mass (ESI-MS): calculated for C4H9NO6P [M-H]-: 198.0166; found: 198.0173. 
 
3.23. Bis(pivaloyloxymethyl)ester of 13 (17) 
To a solution of 34 in CH2Cl2 was added TMSBr (4eq.) dropwise at 0 °C. After one hour the 
icebath was removed and the mixture was stirred at rt for another five hours. All volatiles 
were removed under vacuum, the residual oil was redissolved in THF and treated with water . 
After five minutes the solvent was evaporated and the residue was dried in vacuo overnight. 
For the alkylation step, the resulting oil was dissolved in anhydrous DMF, treated with 
triethylamine and stirred for ten minutes. Chloromethyl pivalate was added and the mixture 
was stirred at 70 °C for 6.5 h, then at room temperature during the weekend. DMF was 
removed under reduced pressure and the residue was taken up in diethyl ether, filtered and 
extracted with water and saturated NaHCO3-solution. The organic layer was dried over 
anhydrous MgSO4 and the solvent was removed under reduced pressure. The resulting oil was 
purified by flash chromatography on silica gel with diethyl ether as an eluent. Benzyl 
deprotection was performed in ethyl acetate with H2 at atmospheric pressure and Pd/C 10% as 
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a catalyst. After hydrogenating for four hours at room temperature the mixture was filtered 
over a celite pad, the solvent was evaporated and the resulting oil was purified by column 
chromatography on silica gel (Et2O to Et2O:EtOAc 1:1) to give 17 as a slightly purple oil in 
56% yield. 
1H-NMR (300 MHz, CDCl3): δ = 1.23 (s, 18H, (CH3)3C(O)O), 3.26 (br.s, 3H, NCH3), 4.00 (d, 
JC,P = 6.6 Hz, 2H, CH2P), 4.41 (s, 2H, C(O)CH2O), 5.70 (m, 4H, (CH2O)2P), 8.23 (br.s, 1H, 
NOH) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 27.02 ((CH3)3), 36.11 (NCH3), 38.95 (C(CH3)3), 65.20 (d, 
JCP = 165.59 Hz, CH2P), 70.07 (d, JCP =9.96 Hz, C(O)CH2O), 82.08 (d, JCP =6.64 Hz, 
OCH2O), 169.66 (C(O)N), 177.13 (C(O)O) ppm. 
31P-NMR (121 MHz, CDCl3): δ = 22.91 (s) ppm. 
Exact mass (ESI-MS): calculated for C16H29NO10P [M-H]-: 428,16799; found: 428.16729. 
 
3.24. Biological assays 
3.24.1. DOXP reductoisomerase inhibition assay 
The assay was performed in a reaction mixture containing 100 mM Tris HCl (pH 7.5), 0.2 % 
bovine serum albumin, 1 mM MnCl2, 1 mM DOXP, 0.3 mM NADPH, and 1 µg/ml 
recombinant DOXP reductoisomerase of E. coli. The mixture without substrate was pre-
incubated with a serial dilution of the test compounds on a 96 well plate at 30 °C for 5 min. 
The compounds had been dissolved in 100 mM Tris HCl (pH 7.5) and pre-diluted to the 10-
fold final concentrations on a separate plate. The reaction was started by the addition of 
DOXP. The decrease of absorption was monitored at 340 nm using a SpectraMax 340PC 
microplate reader (Molecular Devices). 
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3.24.2. In vitro culture of P. falciparum  
P. falciparum parasites were cultured in RPMI 1640 medium supplemented with 10% human 
serum and 25 mM HEPES buffer.18
 
 Human erythrocytes served as host cells. For maintenance 
of the culture, Petri dishes with 10 cm diameter were used. Each Petri dish contained 10 ml 
medium with a haematocrit of 5%. The cultures were incubated at 37 °C under an atmosphere 
of 5% O2, 3% CO2 and 92% N2. The medium was changed daily, and the cultures diluted at a 
maximal parasitaemia of 5%. The parasitaemia was checked microscopically using Giemsa-
stained smears.   
3.24.3. In vitro determination of antimalarial activity  
For the in vitro determination of antimalarial activity a 96-well plate assay was used 
(Desjardins et al. 1979; Ancelin et al. 1998).19
 
 To each well 0.2 ml of a suspension of P. 
falciparum infected erythrocytes with 2% haematocrit and 0.4% parasitaemia were added. 
Then, a serial dilution of the test compounds was prepared on the plate. After incubation for 
48 h, 0.8µ Ci [3H]hypoxanthine in 50 µl medium were added to each well. The plates were 
further incubated for 24 h. The parasites were collected on glass fibre filters using a cell 
harvester (Micromate 196, Packard). The incorporated radioactivity was measured with a -
counter (Matrix 9600, Packard).  
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Figure 1. The conversion of 1-deoxy-D-xylulose 5-phosphate (DOXP, 1) to 2-C-methyl-D-
erythritol 4-phosphate (MEP, 3) by deoxyxylulose 5-phosphate reductoisomerase (DXR). 
 
Chart 1. Structures of fosmidomycin, FR900098, reported and synthesized analogues. 
 
Scheme 1. Reagents and conditions: (a) acetyl chloride, CH2Cl2, Et3N, 0 °C or 
carbonyldiimidazole, HCOOH, rt; (b) paraformaldehyde, tBuOK, 60 °C; (c) SOCl2, CH2Cl2, 
10 °C; (d) paraformaldehyde, Et3N, 90 °C;  (e) CH2Cl2, rt; (f) H2, Pd/C, MeOH, rt. 
 
Scheme 2. Reagents and conditions: (a) ethylbromoacetate, NaH, DMF, 60 °C;  (b) NaOH, 
H2O, rt; (c) carbonyldiimidazole, BnONH2·HCl, Et3N, rt; (d) MeI, NaH, rt; (e) H2, Pd/C, 
MeOH, rt; (f) TMSBr, CH2Cl2, rt. 
  
Scheme 3. Reagents and conditions: (a) carbonyldiimidazole,NH2OBnּHCl, Et3N, rt; (b) MeI, 
NaH, rt; (c) H2, Pd/C, MeOH, rt; (d) TMSBr, CH2Cl2, rt. 
 
Scheme 4. Reagents and conditions: (a) (i) TMSBr in CH2Cl2 6h, 0 °C to rt, then H2O in 
THF, rt; (ii) (CH3)3CC(O)OCH2Cl, Et3N, DMF, 70 °C to rt, 2d; (iii) H2, Pd/C, EtOAc, rt 
 
Table 1. IC50 values against recombinant E. coli DXR and in vitro growth inhibition of a 3D7 
P. falciparum strain. 
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compound IC50 (μM) E. coli DXRa 
IC50 (µM)  
3D7a  
9 0.097 ± 0.012 0.98 ± 0.06 
10 1.11 ± 0.14 4.9 ± 0.4 
11 0.087 ± 0.015 0.36 ± 0.02 
12 >3  
13 0.072 ± 0.012 0.24 ± 0.09 
14 >3  
15 >3  
16 >30 0.099 ± 0.012 
17 >30 0.051 ± 0.010 
fosmidomycin 0.054 ± 0.012 1.20 ± 0.18 
FR900098 0.062 ± 0.012 0.43 ± 0.06 
 aMean values ±  standard deviation of 3 to 5 independent measurements  
 
Table 1 
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